Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-center, Open Label Trial of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder

NCT02893111 is registered in ClinicalTrials.gov with Tianjin Medical University General Hospital as lead sponsor.

NCT NCT02893111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02893111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-center, Open Label Trial of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder
Lead sponsor
Tianjin Medical University General Hospital
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2015
Completion date
January 31, 2017
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuromyelitis optica spectrum disorder